GET THE APP

A novel dual-targeted and biomimetic Doxorubicin nanocarrier | Abstract

Asian Journal of Pharmaceutical Technology and Innovation (ajpti)

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

A novel dual-targeted and biomimetic Doxorubicin nanocarrier

Abstract

Guliz Ak

Epithelial ovarian cancer is the leading cause of death among gynecologic malignancies. Ovarian cancer cells can develop folate receptors that are not overexpressed on somatic cells, making it possible to exploit these receptors for anticancer therapy. In addition, magnetic agents can be directed to tumor tissues via an external magnetic field and this may mostly eliminate the side effects of classical oral treatment. Doxorubicin is used for ovarian cancer therapy but its usage is limited due to the side effects. Recent advances in molecular and cellular biology have inspired scientists and nanotechnologists to model nanocarriers after red blood cells, which are nature’s long circulating delivery vehicles. Properties of red blood cells such as their structure and surface proteins have been taken as design cues to devise the next-generation delivery platforms. In this work, we aimed to design a novel biomimetic doxorubicin nanocarrier system that targeted with magnetically and biomolecularly via folate ligand for ovarian cancer therapy. Magnetic nanoparticles were prepared with the combination of magnetite, polysaccharide and polyethylene glycol. Doxorubicin was loaded to this carrier system. Finally, red blood cells and folate ligand were used to acquire biomimetic properties and biomolecularly targeting, respectively. This biomimetic doxorubicin nanocarrier could have potential for effective ovarian cancer treatment. Acknowledgement: We would like to thank for financial support received from the Research Foundation of Ege University

Share this article